BIOKIER, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.biokier.com
Pharmacokinetics of Butyrate Tablet BKR-017
Not yet recruiting
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- BioKier Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06556745
Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Dietary Supplement: BKR-017
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- BioKier Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04673656
- Locations
- 🇺🇸
Duke Clinical Research at Pickett Road, Durham, North Carolina, United States
🇺🇸Duke Clinical & Translational Science Institute (CTSI), Kannapolis, North Carolina, United States
🇺🇸Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Effects of BKR-017 on Insulin Resistance in Type 2 Diabetes Patients
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Dietary Supplement: BKR-017
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- BioKier Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04279444
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Effect of BKR-013 on Average Daily Glucose Levels
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Other: BKR-013 or Placebo
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- BioKier Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03382015
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
© Copyright 2025. All Rights Reserved by MedPath